Illumina ($ILMN), a gene sequencer and diagnostics company, will renew a push to continue its patent fight against Complete Genomics ($GNOM). The U.S. District Court for the Northern District of California granted the company's request to file a motion seeking reconsideration of its October ruling invalidating patent claims against Complete Genomics. Previously, the court invalidated two of Illumina's claims. The continued court fight comes after Complete Genomics rebuffed a takeover bid from Illumina in favor of a Chinese suitor. Release